Drugs / AlloRx

Trials 26 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 126 trials
Phase 1 NCT05018832 Dec 2025 → Nov 2028 expected traumatic brain injury The Foundation for Orthopaedics and Regenerative Medicine Not yet recruiting No outcome recorded
Phase 1 NCT05158127 Dec 2025 → Dec 2028 expected ulcer disease The Foundation for Orthopaedics and Regenerative Medicine Not yet recruiting No outcome recorded
Phase 1 NCT05018858 Dec 2025 → Oct 2028 expected lupus erythematosus The Foundation for Orthopaedics and Regenerative Medicine Recruiting No outcome recorded
Phase 1 NCT05003921 Dec 2025 → Sep 2028 amyotrophic lateral sclerosis The Foundation for Orthopaedics and Regenerative Medicine Suspended No outcome recorded
Phase 1 NCT05158933 Apr 2025 ovarian dysfunction The Foundation for Orthopaedics and Regenerative Medicine Withdrawn No outcome recorded
Phase 1 NCT05158114 Apr 2025 oligospermia, testicular disorder The Foundation for Orthopaedics and Regenerative Medicine Withdrawn No outcome recorded
Phase 1 NCT05018793 Dec 2024 → Dec 2028 expected spinal cord injury The Foundation for Orthopaedics and Regenerative Medicine Recruiting No outcome recorded
Phase 1 NCT06143527 Nov 2023 → Nov 2027 expected polycystic ovary syndrome The Foundation for Orthopaedics and Regenerative Medicine Recruiting No outcome recorded
Phase 1 NCT05152381 Dec 2022 → Apr 2025 osteoporosis The Foundation for Orthopaedics and Regenerative Medicine Withdrawn No outcome recorded
Phase 1 NCT05147675 Dec 2022 → Dec 2027 expected osteoarthritis The Foundation for Orthopaedics and Regenerative Medicine Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 26 sources stand behind the page.

FieldValueCited text
Known as AlloRx “Biological: AlloRxNCT05147766
25

NCT05016804

NCT05147779

NCT05003921

NCT05003934

NCT05003947

NCT05003960

NCT05158127

NCT05018845

NCT05018858

NCT05018767

NCT05018832

NCT05003908

NCT05158114

NCT05018819

NCT05158439

NCT05018793

NCT05147688

NCT05147675

NCT05003388

NCT05152290

NCT05152381

NCT06143527

NCT05147701

NCT05158933

NCT05016817

Known as UC-MSCs “This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for...” NCT05158933
1

“This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for...” NCT05018845

Modality Cell therapy “cultured allogeneic adult umbilical cord derived mesenchymal stem cells” NCT05003388
Route Intravenous intravenous infusion” NCT05003388